Skip to content
Triangle logo TriangleGet started
← Plasma Cell Neoplasms

NCT00400686 · STUDY IN CONTEXT

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.

Source null

→

primary · POSTED

Number of Patients With an at Least 1gm/dL Increase in Hgb

Source null

→

primary · POSTED

Number of Patients With an at Least 2gm/dL Increase in Hgb

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-plasma-cell-neoplasms
nct id
NCT00400686
trial label
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
3
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    outcome key
    om-0000
    source section id
    NCT00400686-om-0000
    source outcome index
    0
    endpoint
    Change From Baseline in Hemoglobin at Day 28
    endpoint definition
    Change from baseline in hemoglobin after treatment with high-dose Epoetin Alfa.
    time origin
    Baseline to Day 28
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    outcome key
    om-0001
    source section id
    NCT00400686-om-0001
    source outcome index
    1
    endpoint
    Number of Patients With an at Least 1gm/dL Increase in Hgb
    endpoint definition
    Number of Patients With an at Least 1gm/dL Increase in Hgb
    time origin
    Baseline to Day 28
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    outcome key
    om-0002
    source section id
    NCT00400686-om-0002
    source outcome index
    2
    endpoint
    Number of Patients With an at Least 2gm/dL Increase in Hgb
    endpoint definition
    Number of Patients With an at Least 2gm/dL Increase in Hgb
    time origin
    Baseline to Day 28
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Epoetin Alfa - 80,000 U sc
    regimen
    Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00400686-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Epoetin Alfa - 80,000 U sc
    regimen
    Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00400686-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Epoetin Alfa - 80,000 U sc
    regimen
    Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels epoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
    analyzed count
    31
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00400686-om-0002#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-plasma-cell-neoplasms
    nct id
    NCT00400686
    harm key
    EG000
    source section id
    NCT00400686-ae
    event group key
    EG000
    event group label
    Epoetin Alfa - 80,000 U sc
    serious affected
    0
    serious at risk
    31
    other affected
    3
    other at risk
    31
    frequency threshold
    5
    collection period
    AE data highlights development of VTEs in patients receiving one of the following: 1. lenalidomide, high dose dexamethasone & Aspirin 325mg daily 2. thalidomide & doxil based therapy with aspirin 81mg daily 3. cyclophosphamide & prednisone without VTE
    event definition
    Only immediately reportable Serious Adverse Events (SAE) \& Venous thrombolytic event (VTE) were captured for the purpose of this study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice